Oncolytic Viruses for Cancer Therapy: Barriers and Recent Advances

Overview

Journal Mol Ther Oncolytics

Publisher Cell Press

Date 2019 Dec 25

PMID 31872046

Citations 133

Authors

Meijun Zheng

Jianhan Huang

Aiping Tong

Hui Yang

Affiliations

Soon will be listed here.

Abstract

Oncolytic viruses (OVs) are powerful new therapeutic agents in cancer therapy. With the first OV (talimogene laherparepvec [T-vec]) obtaining US Food and Drug Administration approval, interest in OVs has been boosted greatly. Nevertheless, despite extensive research, oncolytic virotherapy has shown limited efficacy against solid tumors. Recent advances in viral retargeting, genetic editing, viral delivery platforms, tracking strategies, OV-based gene therapy, and combination strategies have the potential to broaden the applications of oncolytic virotherapy in oncology. In this review, we present several insights into the limitations and challenges of oncolytic virotherapy, describe the strategies mentioned above, provide a summary of recent preclinical and clinical trials in the field of oncolytic virotherapy, and highlight the need to optimize current strategies to improve clinical outcomes.

Citing Articles

Chimeric Ad5/35 oncolytic adenovirus overcome preexisting neutralizing antibodies and enhance tumor targeting efficiency.

Dai Z, Si Y, Xiong S, Li Y, Ye J, Gao Q Cancer Gene Ther. 2025; .

PMID: 40057574 DOI: 10.1038/s41417-025-00884-x.

Advances in preclinical and clinical studies of oncolytic virus combination therapy.

Du W, Na J, Zhong L, Zhang P Front Oncol. 2025; 15:1545542.

PMID: 39990685 PMC: 11842258. DOI: 10.3389/fonc.2025.1545542.

Mesenchymal Stem-Cell-Derived Exosomes as Novel Drug Carriers in Anti-Cancer Treatment: A Myth or Reality?.

Harrell C, Volarevic A, Djonov V, Volarevic V Cells. 2025; 14(3).

PMID: 39936993 PMC: 11817634. DOI: 10.3390/cells14030202.

Recombinant VSVs: A Promising Tool for Virotherapy.

Vorona K, Moroz V, Gasanov N, Karabelsky A Acta Naturae. 2025; 16(4):4-14.

PMID: 39877014 PMC: 11771844. DOI: 10.32607/actanaturae.27501.

Injecting hope: the potential of intratumoral immunotherapy for locally advanced and metastatic cancer.

Skalickova M, Hadrava Vanova K, Uher O, Leischner Fialova J, Petrlakova K, Masarik M Front Immunol. 2025; 15:1479483.

PMID: 39850897 PMC: 11754201. DOI: 10.3389/fimmu.2024.1479483.

References

Martinez M, Moon E . CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment. Front Immunol. 2019; 10:128. PMC: 6370640. DOI: 10.3389/fimmu.2019.00128. View

Lohr M, Muller P, Karle P, Stange J, Mitzner S, Jesnowski R . Targeted chemotherapy by intratumour injection of encapsulated cells engineered to produce CYP2B1, an ifosfamide activating cytochrome P450. Gene Ther. 1999; 5(8):1070-8. DOI: 10.1038/sj.gt.3300671. View

Ajina A, Maher J . Prospects for combined use of oncolytic viruses and CAR T-cells. J Immunother Cancer. 2017; 5(1):90. PMC: 5696728. DOI: 10.1186/s40425-017-0294-6. View

Zamarin D, Holmgaard R, Ricca J, Plitt T, Palese P, Sharma P . Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity. Nat Commun. 2017; 8:14340. PMC: 5316835. DOI: 10.1038/ncomms14340. View

Wu Y, He J, Geng J, An Y, Ye X, Yan S . Recombinant Newcastle disease virus expressing human TRAIL as a potential candidate for hepatoma therapy. Eur J Pharmacol. 2017; 802:85-92. DOI: 10.1016/j.ejphar.2017.02.042. View

Nayyar G, Chu Y, Cairo M . Overcoming Resistance to Natural Killer Cell Based Immunotherapies for Solid Tumors. Front Oncol. 2019; 9:51. PMC: 6378304. DOI: 10.3389/fonc.2019.00051. View

Russell S, Peng K, Bell J . Oncolytic virotherapy. Nat Biotechnol. 2012; 30(7):658-70. PMC: 3888062. DOI: 10.1038/nbt.2287. View

Alvarez-Breckenridge C, Yu J, Caligiuri M, Chiocca E . Uncovering a novel mechanism whereby NK cells interfere with glioblastoma virotherapy. Oncoimmunology. 2013; 2(4):e23658. PMC: 3654589. DOI: 10.4161/onci.23658. View

Ashshi A, El-Shemi A, Dmitriev I, Kashentseva E, Curiel D . Combinatorial strategies based on CRAd-IL24 and CRAd-ING4 virotherapy with anti-angiogenesis treatment for ovarian cancer. J Ovarian Res. 2016; 9(1):38. PMC: 4924320. DOI: 10.1186/s13048-016-0248-5. View

10.

Goradel N, Mohajel N, Malekshahi Z, Jahangiri S, Najafi M, Farhood B . Oncolytic adenovirus: A tool for cancer therapy in combination with other therapeutic approaches. J Cell Physiol. 2018; 234(6):8636-8646. DOI: 10.1002/jcp.27850. View

11.

Hesse A, Kosmides D, Kontermann R, Nettelbeck D . Tropism modification of adenovirus vectors by peptide ligand insertion into various positions of the adenovirus serotype 41 short-fiber knob domain. J Virol. 2006; 81(6):2688-99. PMC: 1865974. DOI: 10.1128/JVI.02722-06. View

12.

Sharp D, Lattime E . Recombinant Poxvirus and the Tumor Microenvironment: Oncolysis, Immune Regulation and Immunization. Biomedicines. 2017; 4(3). PMC: 5298125. DOI: 10.3390/biomedicines4030019. View

13.

Lee E, Jin S, Kang B, Jung Y . Construction of replication-competent oncolytic retroviral vectors expressing R peptide-truncated 10A1 envelope glycoprotein. J Virol Methods. 2019; 268:32-36. DOI: 10.1016/j.jviromet.2019.03.008. View

14.

Guedan S, Rojas J, Gros A, Mercade E, Cascallo M, Alemany R . Hyaluronidase expression by an oncolytic adenovirus enhances its intratumoral spread and suppresses tumor growth. Mol Ther. 2010; 18(7):1275-83. PMC: 2911260. DOI: 10.1038/mt.2010.79. View

15.

Kuryk L, Moller A, Jaderberg M . Combination of immunogenic oncolytic adenovirus ONCOS-102 with anti-PD-1 pembrolizumab exhibits synergistic antitumor effect in humanized A2058 melanoma huNOG mouse model. Oncoimmunology. 2019; 8(2):e1532763. PMC: 6343802. DOI: 10.1080/2162402X.2018.1532763. View

16.

Han J, Chen X, Chu J, Xu B, Meisen W, Chen L . TGFβ Treatment Enhances Glioblastoma Virotherapy by Inhibiting the Innate Immune Response. Cancer Res. 2015; 75(24):5273-82. PMC: 4681611. DOI: 10.1158/0008-5472.CAN-15-0894. View

17.

Ulasov I, Zhu Z, Tyler M, Han Y, Rivera A, Khramtsov A . Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma. Hum Gene Ther. 2007; 18(7):589-602. DOI: 10.1089/hum.2007.002. View

18.

OCathail S, Pokrovska T, Maughan T, Fisher K, Seymour L, Hawkins M . Combining Oncolytic Adenovirus with Radiation-A Paradigm for the Future of Radiosensitization. Front Oncol. 2017; 7:153. PMC: 5523729. DOI: 10.3389/fonc.2017.00153. View

19.

Patel M, Jacobson B, Ji Y, Drees J, Tang S, Xiong K . Vesicular stomatitis virus expressing interferon-β is oncolytic and promotes antitumor immune responses in a syngeneic murine model of non-small cell lung cancer. Oncotarget. 2015; 6(32):33165-77. PMC: 4741756. DOI: 10.18632/oncotarget.5320. View

20.

Pearl T, Markert J, Cassady K, Ghonime M . Oncolytic Virus-Based Cytokine Expression to Improve Immune Activity in Brain and Solid Tumors. Mol Ther Oncolytics. 2019; 13:14-21. PMC: 6453942. DOI: 10.1016/j.omto.2019.03.001. View